Macular Degeneration Therapeutics
Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though
High Unmet Need Remains
GBI
Research has released its research, “ Macular Degeneration Therapeutics Market
in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High
Unmet Need Remains”, which provides in-depth insights into the macular
degeneration market forecast until 2019 for the Asia-Pacific (APAC) region
covering the four countries of Australia, China, India and Japan. It also
covers disease epidemiology; treatment algorithms; treatment patterns; an
in-depth analysis of clinical trials including failure rate analysis, pipeline
analysis; and an analysis of deals relevant to macular degeneration. Apart from
these the report also includes a heat map for the macular degeneration marketed
products.
To check out the complete table of
contents, visit: http://www.marketresearchreports.biz/analysis-details/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains
GBI
Research analysis shows that the APAC ophthalmology market for macular
degeneration was valued at $675.7m in 2012. The market is expected to grow at a
Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will
reach $1,016m by 2019. Increase in the aging population and high annual cost of
therapy of the marketed drugs are expected to drive the market valuations
through 2019. However, the predominant off-label usage of Avastin for the
treatment of the disease especially in developing countries like India and
China act as a major barrier for growth of the market during the forecast
period.
Scope
- Disease overview along with treatment algorithms and treatment usage patterns
- Market size and forecast for the macular degeneration market in APAC from 2012 to 2019
- Major marketed products in the APAC along with a heat map
- In-depth analysis of pipeline along with clinical trial failure analysis
- Key drivers and restraints that have had a significant impact on the market
- Key licensing and co-development agreements in the macular degeneration market
Reasons
to Buy
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table
of Content
1
Table of Contents
1.1
List of Tables
1.2
List of Figures
2
Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1
Symptoms
2.2
Etiology
2.3
Pathophysiology
2.3.1
Disease Initiation
3
Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1
Therapeutic Landscape
3.1.1
Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2
Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3
Avastin (bevacizumab) – Genentech (Roche)
4
Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1
Overall Pipeline
4.2
Pipeline Analysis by Molecule Type
4.3
Pipeline Analysis by Mechanism of Action
4.4
Clinical Trials
4.4.1
Failure Rate
5
Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1
Geographical Markets
5.1.1
APAC Market
5.1.2
Australia
5.1.3
China
6
Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic
Consolidations
6.1
Deals Analysis
6.2
Major Co-development Deals
6.2.1
Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2
Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3
X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine
for AMD
7
Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1
All Pipeline Drugs by Phase
7.1.1
Discovery
7.1.2
Preclinical
7.1.3
IND-filed and Phase 0
Latest Reports:
Small
Cells and Femtocells: Market Shares, Strategies, and Forecasts, Worldwide, 2013
to 2019: http://www.marketresearchreports.biz/analysis-details/small-cells-and-femtocells-market-shares-strategies-and-forecasts-worldwide-2013-to-2019
WinterGreen
Research announces that it has published a new study Small Cells and
Femtocells: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019.
The 2013 study has 413 pages, 162 tables and figures. Worldwide markets are
poised to achieve significant growth as small cell and femtocells and trucks
permit users to implement automated driving.
Small
cells are better than base stations for expanding wireless infrastructure
coverage in the ear of smart phones. Wireless signals have incremental strength
added locally in home, airport, or enterprise.
Small
cells are able to offload traffic from the macro network to an underlay network
at a street and indoor level. Small cells work for individual subscribers,
public places, and enterprises. Small cells create a wireless signal
transmission zone. A cluster of low-power access points are connected to a
local controller. The quality of voice calls and data transmission is improved
in a cost effective manner
Small
cells are units that address wireless services operator needs to continue to
support of mix of 3G and 4G subscriber device generations and a mix of 3G and
4G technology within the same device. LTE standards for data are well
established but wireless devices, smart phones still use 3G for voice services,
creating a need for 3G and 4G transmission capability.
Delivery
of voice services over LTE networks has not been standardized yet. Operators
continue to deliver voice via their 3G networks even as they move data to LTE.
As a result, subscriber devices are a mix of 3G-only and 4G plus 3G, with very
few 4G-only devices. To support these subscribers comprehensively across all
types of mobile services, operators must deploy a multi-mode radio access
infrastructure including multimode femtocells.
Robot Cars and Trucks: Market Shares,
Strategies, and Forecasts, Worldwide, 2013 to 2019: http://www.marketresearchreports.biz/analysis-details/robot-cars-and-trucks-market-shares-strategies-and-forecasts-worldwide-2013-to-2019
WinterGreen
Research announces that it has published a new study Robot Cars and Trucks:
Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. The 2013 study
has 362 pages, 144 tables and figures. Worldwide markets are poised to achieve
significant growth as robot cars and trucks permit users to implement automated
driving.
IBM
and Google are sure to be a significant software vendors for all the robot car
and truck market participants. IBM has a huge head start with its excellent
middleware branded integrated solutions that are hardened and reliable.
As
automated process hits the auto industry as a disruptive force, it parallels
the automated piloting of the airline industry that saw significant labor
savings implementation. Automated vehicle driving can be done anywhere just by
connecting the car to the adaptive cruise control, adaptive steering and braking,
and lane assist systems.
Robot
cars and trucks incrementally add automated process to driving. As software is
added to cars and trucks it is done in concert with modification to the
steering, breaking, and other automotive systems. Autonomous functions for
vehicles are increasingly adopted.
Change
is incremental, we do not have fully functioning robot cars immediately,
rather, steering, collision avoidance, parking, test driving, series of camera
and radar based monitoring systems, lane assist, and adaptive cruise control
are being implemented, presaging rapid adoption of robot cars and trucks as the
various functions mature and work in the real world.
About Us
MarketResearchReports.Biz is the most comprehensive
collection of market research reports. MarketResearchReports.Biz services are specially
designed to save time and money for our clients. We are a one stop solution for
all your research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve all
sizes and types of companies spanning across various industries.
Contact
M/s
Sheela
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
– Canada Toll Free: 866-997-4948
Blog:
http://industry-research-reports.blogspot.com/
No comments:
Post a Comment